title: Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets.
abstract: OBJECTIVE
  To evaluate the effect of growth hormone treatment on final height, phosphate metabolism, bone markers, and bone mineral density in children with X-linked hypophosphatemic rickets.
  
  
  METHODS
  Six patients (aged 7.8 +/- 1.8 years; height z score, -3.4 +/- 0.5) received conventional treatment (1,25-dihydroxyvitamin D(3) plus phosphate salts) combined with growth hormone (0.6-0.9 IU/kg per week, subcutaneously) (group A); 6 patients (aged 7.9 +/- 2.5 years; height z score, -2.1 +/- 0.6, P <.01 with respect to group A) received only conventional treatment (group B).
  
  
  RESULTS
  Final height z score significantly improved in group A (-2.4 +/- 0.5, P <.03 with respect to the value at entry), whereas it did not change in group B (-2.8 +/- 0.5, P = NS). At final height, degree of body disproportion was similar between the groups (group A, 1.3 +/- 0.2; group B, 1.2 +/- 0.1; P = NS). Phosphate retention, bone markers, and radial bone mineral density increased only in group A. No adverse effects were observed.
  
  
  CONCLUSIONS
  In poorly growing patients with X-linked hypophosphatemic rickets, growth hormone therapy combined with conventional treatment improves final height, phosphate retention, and radial bone mineral density, but it does not influence degree of body disproportion.
authors.affiliation: Endocrine Unit, Division of Pediatrics, Department of Reproductive Medicine and Pediatrics, University of Pisa, Pisa, Italy.
authors.forename: G I
authors.initials: GI
authors.lastname: Baroncelli
authors.forename: S
authors.initials: S
authors.lastname: Bertelloni
authors.forename: C
authors.initials: C
authors.lastname: Ceccarelli
authors.forename: G
authors.initials: G
authors.lastname: Saggese
mesh_terms: D000293:Adolescent; D015415:Biomarkers / Q000032:analysis; D001827:Body Height / Q000187:drug effects*; D015519:Bone Density / Q000187:drug effects*; D002117:Calcitriol / Q000008:administration & dosage; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007015:Hypophosphatemia, Familial / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010710:Phosphates / Q000008:administration & dosage / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D015415:Biomarkers; D010710:Phosphates; D011994:Recombinant Proteins; D013006:Growth Hormone; D002117:Calcitriol